A

ABL Bio Inc
KOSDAQ:298380

Watchlist Manager
ABL Bio Inc
KOSDAQ:298380
Watchlist
Price: 27 400 KRW 3.79% Market Closed
Market Cap: 1.3T KRW
Have any thoughts about
ABL Bio Inc?
Write Note

ABL Bio Inc
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

ABL Bio Inc
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
A
ABL Bio Inc
KOSDAQ:298380
Income from Continuing Operations
-â‚©35.9B
CAGR 3-Years
12%
CAGR 5-Years
27%
CAGR 10-Years
N/A
Celltrion Inc
KRX:068270
Income from Continuing Operations
â‚©183.8B
CAGR 3-Years
-31%
CAGR 5-Years
-5%
CAGR 10-Years
6%
SK Bioscience Co Ltd
KRX:302440
Income from Continuing Operations
â‚©22.3B
CAGR 3-Years
-12%
CAGR 5-Years
20%
CAGR 10-Years
N/A
H
Hugel Inc
KOSDAQ:145020
Income from Continuing Operations
â‚©119.4B
CAGR 3-Years
20%
CAGR 5-Years
17%
CAGR 10-Years
N/A
P
PharmaResearch Co Ltd
KOSDAQ:214450
Income from Continuing Operations
â‚©88.1B
CAGR 3-Years
22%
CAGR 5-Years
40%
CAGR 10-Years
N/A
Alteogen Inc
KOSDAQ:196170
Income from Continuing Operations
-â‚©5.1B
CAGR 3-Years
41%
CAGR 5-Years
11%
CAGR 10-Years
N/A
No Stocks Found

ABL Bio Inc
Glance View

Market Cap
1.3T KRW
Industry
Biotechnology

ABL Bio, Inc. engages in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2018-12-19. The major products include anti-angiogenesis antibodies anti-tumor targeting antibodies, T cell engager bispecific antibodies (TCEs), dual immune cell targeting bispecific antibodies (DICs), novel immune cell targeting antibodies (NICs), brain disease dual antibodies, antibody-drug conjugates (ADCs) , among others.

Intrinsic Value
8 401.38 KRW
Overvaluation 69%
Intrinsic Value
Price
A

See Also

What is ABL Bio Inc's Income from Continuing Operations?
Income from Continuing Operations
-35.9B KRW

Based on the financial report for Jun 30, 2024, ABL Bio Inc's Income from Continuing Operations amounts to -35.9B KRW.

What is ABL Bio Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
27%

Over the last year, the Income from Continuing Operations growth was -9%. The average annual Income from Continuing Operations growth rates for ABL Bio Inc have been 12% over the past three years , 27% over the past five years .

Back to Top